

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 April 2022 (21.04.2022)



(10) International Publication Number
WO 2022/078465 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
C12N 15/13 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/CN2021/123892

(22) International Filing Date:

14 October 2021 (14.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/120869

14 October 2020 (14.10.2020) CN

PCT/CN2020/122188

20 October 2020 (20.10.2020) CN

(71) Applicant (for CN only): **I-MAB BIOPHARMA CO., LTD.** [CN/CN]; Suite 802, West Tower, OmniVision Tech Park, 88 Shangke Road, Shanghai 201210 (CN).

(71) Applicant (for all designated States except CN): **I-MAB BIOPHARMA US LIMITED** [US/US]; 2275 Research Boulevard, Suite 516, Rockville, Maryland 20850 (US).

(72) Inventors: **WANG, Zhengyi**; Suite 802, West Tower, OmniVision Tech Park, 88 Shangke Road, Shanghai 201210 (CN). **CAO, Wei**; Suite 802, West Tower, OmniVision Tech Park, 88 Shangke Road, Shanghai 201210 (CN). **GUO, Bingshi**; Suite 802, West Tower, OmniVision Tech Park, 88 Shangke Road, Shanghai 201210 (CN). **XU, Cong**; 2275 Research Boulevard, Suite 516, Rockville, Maryland 20850 (US).

(74) Agent: **BEIJING CAIHE LAW FIRM**; Room 1602, Fuhai International Plaza, No. 17 Daliushu Road, Haidian District, Beijing 100081 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

WO 2022/078465 A1

(54) Title: NOVEL ANTI-CD47 ANTIBODIES AND USES THEREOF

(57) Abstract: Provided herein are CD47 antibodies and immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination. Also provided are as well as pharmaceutical compositions containing such antibodies or antibody fragments, as well as methods of treatment using such antibodies, e.g., as single agents or in combination with other therapeutic agent (s).